BiotechTube

dabrafenib/trametinib

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Thyroid Cancer

Conditions

Anaplastic Thyroid Cancer

Trial Timeline

Jan 1, 2023 → Jan 1, 2028

NCT ID
NCT06079333

About dabrafenib/trametinib

dabrafenib/trametinib is a phase 2 stage product being developed by Novartis for Anaplastic Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06079333. Target conditions include Anaplastic Thyroid Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Thyroid Cancer were approved

Approved (0) Terminated (0) Active (1)
🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06079333Phase 2Recruiting

Competing Products

20 competing products in Anaplastic Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
Lenvatinib 24 mgEisaiPhase 2
27
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
LDK378 + AUY922NovartisPhase 1
29
ceritinibNovartisPre-clinical
30
LDK378NovartisPhase 1
29
CeritinibNovartisPhase 2
27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
29
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
44
Sunitinib MalatePfizerPhase 2
35
Crizotinib (PF-02341066)PfizerPhase 2
35
LorlatinibPfizerPhase 2
31
CrizotinibPfizerPhase 1/2
32
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
36
Etirinotecan pegolNektar TherapeuticsPhase 2
29
BevacizumabNovocurePhase 2
36